Total Payments
$90,345
2024 Payments
$17,300
Companies
14
Transactions
97
Medicare Patients
970
Medicare Billing
$327,785
Payment Breakdown by Category
Consulting$75,140 (83.2%)
Travel$12,910 (14.3%)
Food & Beverage$2,276 (2.5%)
Education$19.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $75,140 | 37 | 83.2% |
| Travel and Lodging | $12,910 | 20 | 14.3% |
| Food and Beverage | $2,276 | 39 | 2.5% |
| Education | $19.81 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $34,479 | 34 | $0 (2024) |
| Genentech USA, Inc. | $15,235 | 10 | $0 (2023) |
| AstraZeneca UK Limited | $13,836 | 22 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $7,415 | 6 | $0 (2024) |
| Janssen Global Services, LLC | $4,188 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,050 | 1 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,516 | 8 | $0 (2020) |
| Janssen Biotech, Inc. | $3,218 | 4 | $0 (2024) |
| Gilead Sciences, Inc. | $1,974 | 3 | $0 (2023) |
| Genentech, Inc. | $1,100 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,300 | 17 | AstraZeneca Pharmaceuticals LP ($12,667) |
| 2023 | $11,911 | 14 | AstraZeneca Pharmaceuticals LP ($3,138) |
| 2022 | $12,971 | 8 | AstraZeneca Pharmaceuticals LP ($5,206) |
| 2021 | $12,518 | 10 | Janssen Scientific Affairs, LLC ($4,040) |
| 2020 | $11,165 | 6 | Genentech USA, Inc. ($5,500) |
| 2019 | $11,405 | 26 | AstraZeneca Pharmaceuticals LP ($6,227) |
| 2018 | $8,606 | 11 | AstraZeneca UK Limited ($8,572) |
| 2017 | $4,469 | 5 | Genentech USA, Inc. ($4,469) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,460.00 | General |
| 11/13/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 06/01/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $125.79 | General |
| Category: Oncology | ||||||
| 05/14/2024 | Janssen Global Services, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 03/01/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $5,480.00 | General |
| Category: Oncology | ||||||
| 02/28/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 02/23/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $32.29 | General |
| Category: Oncology | ||||||
| 02/22/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $102.37 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $351.18 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $351.18 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $248.39 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $80.18 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $52.39 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $49.25 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $45.26 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: Oncology | ||||||
| 02/14/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 11/11/2023 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 11/10/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $103.91 | General |
| Category: Oncology | ||||||
| 11/10/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $44.16 | General |
| Category: Oncology | ||||||
| 06/11/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 06/07/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $1,890.00 | General |
| Category: ONC | ||||||
| 06/07/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $20.95 | General |
| Category: ONC | ||||||
| 06/05/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 06/04/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $63.49 | General |
| Category: ONC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 221 | 533 | $380,420 | $80,048 |
| 2022 | 5 | 245 | 591 | $376,610 | $78,919 |
| 2021 | 7 | 322 | 804 | $431,320 | $112,607 |
| 2020 | 5 | 182 | 477 | $201,350 | $56,210 |
Total Patients
970
Total Services
2,405
Medicare Billing
$327,785
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 120 | 407 | $301,180 | $63,128 | 21.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 46 | 46 | $38,280 | $8,777 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 60 | $31,800 | $6,023 | 18.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 20 | $9,160 | $2,121 | 23.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 102 | 275 | $203,500 | $42,141 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 236 | $125,080 | $25,540 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $23,240 | $5,512 | 23.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 41 | $15,990 | $3,763 | 23.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $8,800 | $1,963 | 22.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 117 | 300 | $197,850 | $49,654 | 25.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 252 | $119,660 | $28,949 | 24.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 106 | $41,340 | $9,968 | 24.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 44 | 44 | $36,520 | $9,135 | 25.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 11 | 53 | $8,480 | $8,519 | 100.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 26 | $20,800 | $4,845 | 23.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 23 | $6,670 | $1,537 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 68 | 254 | $109,220 | $24,909 | 22.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 66 | 117 | $59,670 | $15,105 | 25.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 17 | 71 | $11,360 | $11,262 | 99.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 20 | 20 | $16,600 | $3,902 | 23.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 15 | $4,500 | $1,032 | 22.9% |
About Catherine Shu
Catherine Shu is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2009. The National Provider Identifier (NPI) number assigned to this provider is 1063655108.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Catherine Shu has received a total of $90,345 in payments from pharmaceutical and medical device companies, with $17,300 received in 2024. These payments were reported across 97 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($75,140).
As a Medicare-enrolled provider, Shu has provided services to 970 Medicare beneficiaries, totaling 2,405 services with total Medicare billing of $327,785. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 04/17/2009
- Last Updated 06/14/2016
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1063655108
Products in Payments
- TAGRISSO (Drug) $20,142
- RYBREVANT (Drug) $6,371
- Non-Covered Product (Drug) $5,500
- IMFINZI (Drug) $4,625
- IMFINZI (Biological) $4,540
- Avastin (Biological) $4,469
- EXKIVITY (Drug) $4,050
- GILOTRIF (Drug) $3,516
- Tecentriq (Biological) $3,056
- TECENTRIQ (Biological) $2,750
- Trodelvy (Drug) $1,974
- Neulasta (Biological) $33.53
- KEYTRUDA (Biological) $19.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555